Get startedLog in
    Picture of Sichuan Kelun-Biotech Biopharmaceutical Co logo

    6990 — Sichuan Kelun-Biotech Biopharmaceutical Co Income Statement

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareHighly SpeculativeLarge CapMomentum Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Sichuan Kelun-Biotech Biopharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:PROSPECTUSPROSPECTUSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue32.38041,5401,9332,058
    Cost of Revenue
    Gross Profit11.85277591,2741,479
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses8101,2221,9242,0722,408
    Operating Profit-777-419-383-139-350
    Total Net Non Operating Interest Income / Expense
    Net Income Before Taxes-890-567-468-143-356
    Provision for Income Taxes
    Net Income After Taxes-890-616-574-267-382
    Net Income Before Extraordinary Items
    Net Income-890-616-574-267-382
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-890-616-574-267-382
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-4.12-2.84-2.53-1.2-1.66